Tenax Therapeutics, Inc. financial data

Symbol
TENX on Nasdaq
Industry
Pharmaceutical Preparations
Location
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC
State of incorporation
DE
Fiscal year end
December 31
Former names
OXYGEN BIOTHERAPEUTICS, INC. (to 9/15/2014), SYNTHETIC BLOOD INTERNATIONAL INC (to 6/30/2008)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 611 % -28.3%
Debt-to-equity 19.6 % +42.9%
Return On Equity 124 % -46.8%
Return On Assets 103 % -49.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.41M shares -85.7%
Common Stock, Shares, Outstanding 1.96M shares -91.8%
Entity Public Float 7.03M USD +40.5%
Common Stock, Value, Issued 196 USD -91.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.77M USD +148%
General and Administrative Expense 5.27M USD +3.15%
Operating Income (Loss) 8.3M USD +60.6%
Net Income (Loss) Attributable to Parent 12.6M USD -34.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.4M USD +85.3%
Other Assets, Current 50.3K USD -82.2%
Assets, Current 10.6M USD -24.4%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 1.12K USD 0%
Assets 10.6M USD -24.4%
Accounts Payable, Current 870K USD +321%
Employee-related Liabilities, Current 432K USD +937%
Accrued Liabilities, Current 592K USD +118%
Liabilities, Current 1.74M USD +111%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.74M USD +111%
Retained Earnings (Accumulated Deficit) -305M USD -4.31%
Stockholders' Equity Attributable to Parent 8.88M USD -32.9%
Liabilities and Equity 10.6M USD -24.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.72M USD +41.3%
Net Cash Provided by (Used in) Financing Activities 7.92M USD -43.5%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 1.96M shares -91.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.72M USD -0.07%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.38M USD -29.9%
Deferred Tax Assets, Valuation Allowance 38.7M USD +3.08%
Operating Lease, Liability 0 USD -100%
Depreciation 7.57K USD +68.8%
Payments to Acquire Property, Plant, and Equipment 1.24K USD -80.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 11M USD
Lessee, Operating Lease, Liability, to be Paid 228K USD -35.6%
Operating Lease, Liability, Current 116K USD +11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 65.7K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 130K USD +2.52%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, to be Paid, Year Three 130K USD +2.52%
Deferred Tax Assets, Operating Loss Carryforwards 36.8M USD +2.02%
Preferred Stock, Shares Issued 10M shares
Preferred Stock, Shares Authorized 4.82M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 65.7K USD -49.4%
Additional Paid in Capital 314M USD +2.7%
Preferred Stock, Shares Outstanding 5.18M shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 24.6K USD +46.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares